Is genetic testing for ADHD available clinically?

PostedOctober 8, 2025

UpdatedOctober 10, 2025

ByMy Patient Advice

Author: Victoria Rowe, MSc | Reviewed by: Dr. Rebecca Fernandez, MBBS

Yes, clinical ADHD genetic testing is now available in certain healthcare settings, offering valuable insights into the genetic factors that contribute to ADHD. While this type of testing is still in the early stages compared to more traditional diagnostic tools, it is becoming increasingly accessible as research advances. Genetic testing can help identify genetic variants associated with ADHD, offering a more personalised approach to diagnostics and treatment.

How Clinical ADHD Genetic Testing Works

Clinical ADHD genetic testing works by analysing DNA for specific gene variants linked to attention regulation and medication response, aiding in personalised treatment planning.

Genetic variants linked to ADHD

Genetic testing for ADHD typically focuses on identifying specific genetic markers that are associated with the disorder, such as variations in dopamine-related genes (like DAT1 and DRD4) and neurodevelopmental genes. These genetic markers can provide insights into an individual’s risk for ADHD, though they are not definitive on their own. Instead, they are used to complement traditional diagnostic approaches, which include behavioural assessments and neuroimaging.

Testing methods and availability

Currently, genetic testing for ADHD is available through specialised clinics or genetic testing companies. The tests often involve a simple blood or saliva sample to assess variations in genes linked to ADHD. However, the clinical application of these tests is still limited, and genetic testing is typically used as part of a comprehensive diagnostic approach rather than a standalone tool.

Why Clinical ADHD Genetic Testing Matters

Clinical ADHD genetic testing matters because it helps tailor medication choices, predict treatment responses, and improve diagnostic accuracy for individual patients.

Personalised diagnostics

By incorporating genetic testing into the diagnostic process, healthcare providers can offer more personalised care for individuals with ADHD. Understanding an individual’s genetic risk can help clinicians tailor treatment strategies, such as choosing medications or therapies that align with the patient’s unique genetic makeup.

Early identification Genetic testing could potentially aid in the early identification of ADHD, particularly in cases where behavioural symptoms are subtle or develop later. For instance, if an individual carries specific genetic markers linked to ADHD, clinicians may monitor their development more closely and intervene earlier, leading to better long-term outcomes.

Improved treatment outcomes

Understanding the genetic underpinnings of ADHD can also help refine treatment plans. Some people may respond better to certain types of medications, while others may benefit from behavioural interventions or cognitive therapies. Clinical ADHD genetic testing helps optimise treatment by identifying which approach is most likely to work for an individual based on their genetic profile.

The Future of Clinical ADHD Genetic Testing

While genetic testing for ADHD is not yet widely available in everyday healthcare practice, its growing presence offers exciting potential for the future of ADHD diagnostics. As the science behind genetic markers for ADHD continues to evolve, we can expect more widespread use in clinical settings, providing a more precise and personalised approach to ADHD care.

Visit providers like ADHD Certify for personal consultations that integrate genetic insights into ADHD management.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Genetic studies and biomarkers.

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.